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ABSTRACT 
 
Aflatoxins are potent hepatotoxic and hepatocarcinogenic agents. This hepatotoxicity is 
thought to be mediated by their ability to generate reactive oxygen species and cause peroxi-
dative damage. In the present investigation we assessed the ability of some natural antioxi-
dants namely, vitamin E and Se, β-carotene, silymarin and coenzyme Q10 on aflatoxin B1 
(AFB1)-induced hepatotoxicity in a rat model. Alanine and aspartate aminotransferases and 
alkaline phosphatase (ALP) were found to be significantly increased in the serum of AFB1 
administered (250 µg/kg body weight/day for 2 weeks) rats, suggesting hepatic damage. 
There was a marked increase in the lipid peroxide levels and a concomitant decrease in the 
hepatic reduced glutathione (GSH) and serum protein thiol (PrSHs) along with a nearly two-
fold increase in hepatic glutathione-S-transferase (GST) activity. The significant increase in 
GST may be attributed to its being a phase ΙΙ enzyme that predominately participates in the 
detoxification of the ultimate electrophilic metabolite AFB1-8, 9 epoxide. On the other hand, 
no significant change was detected in the activities of glutathione peroxidase (GPx), glu-
tathione reductase (GR), glucose-6-phosphate dehydrogenase (G-6-PDH), cytochrome c-
reductase and levels of DNA and RNA in the hepatic tissue of AFB1 administered rats. Re-
sults also revealed that cotreatment with studied antioxidants offered substantial hepatoprotec-
tive effects in the AFB1 administered rats. Moreover, results revealed that vitamin E and sele-
nium combination and β-carotene are more efficient than coenzyme Q10 and silymarin in 
modulating the liver antioxidant enzymatic system. 
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INTRODUCTION 
The aflatoxins are difuranocoumarins 
that are metabolites of a certain strain of 
Aspergillus Flavus (Wogan, 1973). The ma-
jor metabolite AFB1 is hepatotoxic and 
hepatocarcinogenic in several animal spe-
cies at very low doses. The aflatoxins are 
constant contaminants of the human food 
supply in many parts of the world and epi-
demiologically they are linked to an in-
creased incidence of liver cancer in both 
Africa and Asia (Linsell and Peers, 1977; 
Liu et al., 1988). AFB1 and AFM1 were de-
tected in 1.1 % of the food samples repre-
senting 22 different food types that were 
collected from several localities in the Al-
exandria province in Egypt. Thirty two per-
cent of fungal isolates were aflatoxins pro-
ducers (El-Gohary, 1995). The mechanism 
of cellular damage caused by AFB1 has not 
been fully elucidated. A variety of data 
suggests a role for oxidative stress, includ-
ing lipid peroxidation, in the pathogenesis 
of aflatoxicosis (Shen et al., 1994; Towner 
et al., 2002; Sohn et al., 2003; Abdel-
Wahhab et al., 2006; Umarani et al., 2008). 
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AFB1 itself is not mutagenic nor does it 
bind covalently to macromolecules such as 
deoxyribonucleic acid (DNA) in the ab-
sence of a bio-activation system (P450) 
(Massey et al., 1995). AFB1 is subject to 
extensive metabolism in the liver and the 
consequence of exposure to the toxin is de-
termined largely by the capacities of the 
competing activation and detoxification 
biotransformation pathways (McLeod et al., 
1997). AFB1 requires oxidation of the 8, 9 
double bond to yield the biologically active 
AFB1 8,9 epoxide which can react with 
DNA (Gallagher et al., 1994; Guarisco et 
al., 2007).  
Chemoprevention of toxicoses and/or 
cancer using nutrients is the subject of in-
tense study. Among the many compounds 
examined, antioxidants are being investi-
gated because of their ability to reduce dis-
ease formation by either induction or inhi-
bition of key enzyme systems (Guarisco et 
al., 2007). The present study was therefore 
conducted in order to evaluate the effect of 
the hepato-protective agents: β-carotene, 
vitamin E, selenium, silymarin and coen-
zyme Q10 on AFB1-induced hepatic injury 
in rats.  
 
MATERIALS AND METHODS 
Chemicals 
Aflatoxin B1, β-carotene and vitamin E 
were purchased from Sigma-Aldrich 
Chemicals Co., St. Louis, USA. All other 
chemicals were of analytical grade. 
 
Experimental protocol  
Adult male Wistar rats weighing 
160 ± 30 g obtained from the National Re-
search Center Lab. (Cairo, Egypt) were al-
lowed 4-5 days for acclimatization before 
the experiments. Rats were divided into 6 
groups; control group, received an oral 
daily dose of 0.5 % xanthan gum for 2 
weeks. The AFB1 group received an oral 
daily dose of 250 µg AFB1/kg body weight 
for 2 weeks (suspended in xanthan gum) 
(Kensler et al., 1987). The remaining 4 
groups of rats received the same previous 
dose of  AFB1 for the same period simulta-
neously with an oral daily dose of β-
carotene 200 mg/kg body weight (Muto and 
Moriwaki, 1984); silymarin 150 mg/Kg 
body weight (Favari et al., 1997) or coen-
zyme Q10 60 mg/kg body weight (Maru-
yama et al., 1995). The last group received 
vitamin E (300 mg/kg body weight and se-
lenium 2 mg/kg body weight of selenium 
that corresponds to that taken as 6 ppm in 
drinking water (Chen et al., 1982; Shen et 
al., 1994). Rats in all groups were fed by 
intragastric tube. 
At the end of 2 weeks, all animals were 
fasted over night (16-18 hours) with free 
access to water only. The animals were sac-
rificed by decapitation and the blood of 
each animal was collected into a dry centri-
fuge tube. Serum was separated by cen-
trifugation at 3000 r.p.m. for 15 min and 
was used to determine alanine aminotrans-
ferase (ALT), aspartate aminotransferase 
(AST), alkaline phosphatase (ALP) activi-
ties and protein thiol levels (PrSHs). 
The liver was removed, rinsed with ice-
cold saline and blotted dry. A portion of 
liver was homogenized in redistilled water 
using potter elvehjem glass homogenizer 
and divided into five portions. Two portions 
of the homogenate were mixed with 3 % 
m.phosphoric and 2.3 % KCL acid, and 
were centrifuged at 3000 r.p.m for 15 min 
to obtain the supernatants used for assay of 
liver glutathione (GSH) and malondialde-
hyde (MDA) contents, respectively. The 
third portion of the homogenate was mixed 
with Tris-EDTA buffer, pH 7.6 and centri-
fuged at 105,000 xg for 30 min at 4º C to 
isolate the cytosolic fraction used for assay 
of glutathione-S-transferase (GST), gluta-
thione peroxidase (GPx), glutathione reduc-
tase (GR) and glucose-6-phosphate dehy-
drogenase (G-6-PDH) activities. The fourth 
portion was mixed with 0.25 M sucrose so-
lution, centrifuged at 15,000 xg at 4º C for 
20 min for preparing the fraction used for 
cytochrome-c reductase estimation. Finally, 
the fifth portion was mixed with su-
crose/Tris buffer, pH 7.5, for preparing the 
fraction used for DNA and ribonucleic acid 
(RNA) estimation. 
 
EXCLI Journal 2008;7:119-131 – ISSN 1611-2156 
Received: March 28, 2008, accepted: May 04, 2008, published: May 08, 2008 
 
121 
The activities of serum ALT, AST and 
ALP were estimated using commercially 
available kits supplied by bio-Merieux, 
France. Serum levels of PrSHs, hepatic 
GSH and lipid peroxidation (MDA) were 
determined according to the method of 
Koster et al. (1986), Beutler et al. (1963) 
and Uchiyama and Mihara (1978), respec-
tively. Measurement of hepatic activities of 
GST (Habig et al., 1974; Gawai and Pawar, 
1984), GPx (Paglia and Valentine, 1967), 
GR (Long and Carson, 1961), G-6-PDH 
(Glock and McLean (1954) and cyto-
chrome-c reductase (Edelhoch et al., 1952; 
Mahler et al., 1952) were carried out. He-
patic levels of RNA and DNA were esti-
mated according to method of Blobel and 
Potter (1968) and Burton (1956) as modi-
fied by Giles and Myers (1965), respec-
tively. Protein content in liver fractions was 
measured by the method of Lowry et al. 
(1951). 
 
Statistical analysis 
Data were expressed as the mean ± 
S.E.M. Means were compared by one-way 
analysis of variance (ANOVA) followed by 
Duncan test, which was used to identify dif-
ferences between groups. A value of 
P < 0.05 was accepted as significant. 
 
RESULTS 
Data are presented in Table 1, 2 and 3. 
 
Aflatoxin B1  
AFB1 intake caused significant increase 
of serum ALT, AST and ALP and hepatic 
GST activities amounting to 124.6 %, 
108.8 %, 129.5 % and 176.9 %, respec-
tively as compared with control group 
whereas no change in hepatic GPx, GR, G-
6-PDH and cytochrome-c reductase activi-
ties was observed. On the other hand, a sig-
nificant decrease and increase in hepatic 
levels of GSH and MDA was observed 
which amounted to 81.5 % and 202.25 % 
from the control group. A significant reduc-
tion in serum level of protein thiols that 
reached 70.4 % in the control group was 
demonstrated whereas no significant change 
in hepatic levels of DNA and RNA was ob-
served after AFB1 intake. 
 
Vitamin E and selenium combination 
Vitamin E and Se normalized the ele-
vated activities of serum AST and ALP and 
lowered ALT significantly. The change in 
ALT reached 92.1 % as compared to the 
AFB1 group. Co-administration of vitamin 
E and Se induced significant increase in 
hepatic GST, GR and G-6-PDH that 
reached 121 %, 130 % and 119.5 %, respec-
tively from the AFB1 intake group whereas 
no significant increase was observed in 
GPx and cytochrome-c reductase activities 
as compared with the AFB1 group. In addi-
tion, vitamin E and Se intake caused resto-
ration of diminished hepatic GSH level and 
a significant decrease in the elevated he-
patic MDA level that reached 175 % as 
compared with the AFB1 group. On the 
other hand, no change in serum protein 
thiols, liver DNA and RNA levels was ob-
served in the vitamin E+ Se group. 
 
β-Carotene 
β-carotene was found to normalize se-
rum ALP and to lower the elevated ALT 
activity significantly. The change in ALT 
activity was 90.4 % whereas no change in 
serum AST was observed as compared to 
the AFB1-group. Liver GST activity 
showed no significant increase as compared 
to AFB1-group. In addition, a significant 
increase was observed in hepatic GPx, cy-
tochrome-c reductase and GR activities that 
reached 184.7 %, 176.9 % and 132 %, re-
spectively as compared to AFB1 group. The 
results revealed that β-carotene intake re-
stored levels of hepatic GSH, RNA and se-
rum protein thiols relative to control ani-
mals whereas no significant change of 
MDA and DNA levels and G-6-PDH activ-
ity in liver was observed in the β-carotene 
group. 
 
Silymarin 
Silymarin caused normalization of ALT 
and ALP relative to the control group 
whereas a significant decrease of AST ac-
tivity amounted to 86 % was observed as 
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compared to AFB1 group. Moreover, no 
significant change was observed concerning 
hepatic GST, GR, G-6-PDH and cyto-
chrome-c reductase activities. No signifi-
cant increase was detected in the activity of 
hepatic GPx, levels of hepatic GSH, and 
DNA along with serum protein thiols. In 
addition, normalization of the hepatic levels 
of MDA and RNA was detected relative to 
the control animals.  
 
Coenzyme Q10  
Coenzyme Q10 resulted in normalization 
in the activities of serum ALT and AST 
relative to the control group whereas sig-
nificant decrease was demonstrated in ALP 
that amounted to 54.8 % as compared to 
AFB1 group. Significant increase was ob-
served in hepatic GST,GPx and GR activi-
ties that reached 130.6 %, 136.9 % and 
127.4 %, respectively as compared with the 
AFB1 group. Moreover, normalization of 
hepatic level of MDA was achieved relative 
to the control group. On the other hand, no 
significant change in the diminished hepatic 
GSH level, serum level of protein thiols, 
activities of cytochrome c-reductase, G-6-
PDH activity, and levels of DNA and RNA 
in liver was observed as compared to the 
AFB1 group.  
 
Table 1: Effect of AFB1 alone and in combination with vitamin E and selenium, β-carotene, silymarin or 
coenzyme Q10 on serum ALT, AST and ALP activities 
 ALT 
(unit/ml) 
AST 
(unit/ml) 
ALP 
(U/100 ml) 
Control 
  
52.68 ± 0.8 
(33) 
93.1 ± 1.3 
(34) 
40.7 ± 3 
(25) 
AFB1 
  
65.85 ± 1.3 a 
(10) 
101.39 ± 1.4a 
(11) 
52.7 ± 4.3a 
(13) 
AFB1+vitamin E+Se 
 
60.69 ± 1.68 ab 
(11) 
94.19 ± 1.6 b 
(8) 
32.76 ± 2.2 b 
(7) 
AFB1+β-carotene 
  
59.5 ± 3.2 ab 
(9) 
102.6 ± 0.99a 
(8) 
35.56 ± 2.98 b 
(5) 
AFB1+silymarin  
 
55.7 ± 1.4 b 
(9) 
87.5 ± 1.2 ab 
(8) 
35.2 ± 1.5 b 
(8) 
AFB1+coenzymeQ10  
 
53.6 ± 1.7 b 
(9) 
91.53 ± 1.6 b 
(8) 
28.9 ± 3 ab 
(6) 
Values represent mean ± S.E.M. Comparisons are made as follows: (a) with the control group (b) with 
AFB1group. Values are statistically significant at P< 0.05.  Number of observations in each group is 
given between parentheses.  
 
Table 2: Effect of AFB1 alone and in combination with vitamin E and selenium, β-carotene, silymarin 
or coenzyme Q10 on serum PrSHs, liver contents of GSH and MDA as well as activities of GPx and 
GR 
 Serum PrSHs 
 (µmol/L) 
GSH 
(mg/g liver) 
Liver MDA  
(nmoles/mg  
protein) 
GPx 
(U/mg  
protein) 
GR 
(U/mg protein) 
Control  444.39 ± 20.99 
(34) 
2.9 ± 0.009 
(24) 
2.22 ± 0.18 
(15) 
180.19 ± 9.1 
(24) 
68.82 ± 3.46 
(20) 
AFB1  312.88 ± 25.29 a 
(10) 
2.38 ± 0.1 a 
(10) 
4.49±0.4 a 
(8) 
174.96 ± 10.5 
(9) 
69.66 ± 3.7 
(12) 
AFB1+ 
vitamin E+Se 
409.29 ± 64.59 
(6) 
2.9 ± 0.1 b 
(8) 
0.786 ± 0.004ab 
(8) 
204.38 ± 12.89 
(8) 
90.75 ± 6 ab 
(8) 
AFB1+ 
β-carotene  
493.6 ± 25.3 b 
(9) 
3 ± 0.1 b 
(8) 
4.15 ± 0.3 a 
(7) 
323.29 ± 22.8 ab 
(8) 
91.96 ± 4.8 ab 
(7) 
AFB1+ 
silymarin  
400.6 ± 39.55 
(7) 
2.38 ± 0.1 a 
(7) 
2.44 ± 0.39 b 
(8) 
204.39 ± 12.66 
(8) 
70.18 ± 2 
(8) 
AFB1+ 
coenzymeQ10  
327 ± 41.4 a 
(8) 
2.47 ± 0.1 a 
(7) 
2.84 ± 0.45 b 
(10) 
239.6 ± 11.7 ab 
(9) 
88.74 ± 4.6 ab 
(7) 
Values represent mean ± S.E.M. Comparisons are made as follows: (a) with the control group; (b) with 
AFB1group. Values are statistically significant at P < 0.05. Number of observations in each group is 
given between parentheses. 
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Table 3: Effect of AFB1 alone and in combination with vitamin E and selenium, β-carotene, silymarin 
or coenzyme Q10 on hepatic GST, G-6-PDH and cytochrome c-reductase activities as well as DNA and 
RNA levels 
 GST 
(U/mg protein) 
G-6-PDH 
(U/mg protein) 
Cytochrome c-
reductase 
(U/mg protein) 
DNA 
(mg/g liver) 
RNA 
(mg/g liver) 
Control  231.49 ± 12 
(26) 
60.66 ± 3.55 
(16) 
16.29 ± 0.9 
(18) 
2.16 ± 0.22 
(21) 
1.88 ± 0.14 
(28) 
AFB1  409.68 ± 16.19 a 
(12) 
61.2 ± 4.1 
(13) 
15.89 ± 0.9 
(18) 
1.77 ± 0.11 
(18) 
1.6 ± 0.1 
(20) 
AFB1+vitamin E+Se   491.19 ± 38.5 ab 
(8) 
73.17 ± 3.77 ab 
(7) 
13.4 ± 0.6 
(11) 
1.35 ± 0.1 
(11) 
1.6 ± 0.15 
(9) 
AFB1+β-carotene  459.1 ± 21.16 a 
(9) 
60.44 ± 3.2 
(8) 
28.1 ± 1.8 ab 
(8) 
1.77 ± 0.165 
(8) 
2.07 ± 0.1 b 
(9) 
AFB1+silymarin  411.48 ± 16.57 a 
(8) 
60.89 ± 2.8 
(7) 
15.8 ± 2.21 
(8) 
2.36 ± 0.2 
(8) 
2.2 ± 0.16 b 
(8) 
AFB1+coenzymeQ10  535.15 ± 33.3 ab 
(7) 
71.1 ± 4.9 
(7) 
14.37 ± 1 
(10) 
1.65 ± 0.25 
(9) 
1.9 ± 0.19 
(9) 
Values represent mean ± S.E.M. Comparisons are made as follows: (a) with the control group; (b) with 
AFB1group. Values are statistically significant at P < 0.05. Number of observations in each group is 
given between parentheses. 
 
 
DISCUSSION 
Results of the present study revealed 
significant increase in hepatic GST activity 
in the AFB1-received group. This finding is 
in agreement with Kensler et al. (1992) who 
reported that repetitive treatment with AFB1 
alone induced hepatic GST activity and that 
the specific activity of GST was doubled 
after one week of exposure, remaining ele-
vated throughout the AFB1 dosing period. 
The increase in hepatic GST activity is due 
to GSTs being a family of dimeric proteins 
that possess a multitude of functions includ-
ing the enzymatic conjugation of GSH to 
electrophilic xenobiotics (Primiano et al., 
1995). Indeed, GST belongs to phase ΙΙ en-
zymes that in contrast to phase Ι, which can 
participate in both metabolic activation and 
inactivation, predominately participate in 
the detoxification of xenobiotics (Wang et 
al., 1990). It has been known that the harm-
ful effects of AFB1 are a consequence of its 
being metabolized to AFB1-8, 9 epoxide, 
the ultimate electrophilic metabolite that 
serves as an alkylating agent and mutagen 
(Hayes et al., 1991a). In many mammalian 
species, including rats, AFB1-8, 9 epoxide 
is efficiently conjugated with reduced glu-
tathione (Degan and Neumann, 1978), a 
reaction that is catalyzed by GST (Neal and 
Green, 1983). A significant increase in he-
patic MDA, measured as an index of liver 
lipoperoxidation was observed in AFB1-
treated group as shown in Table 2. This 
finding is found to be in agreement with 
other previous studies (Shen et al., 1994; Ip 
et al., 1996; Premalatha et al., 1997; Souza 
et al.,1999; Meki et al., 2001; Umarani et 
al., 2008). The increase in hepatic MDA 
level may be attributed to the fact that 
AFB1 is metabolized by the cellular cyto-
chrome P450 enzyme system to form the 
reactive intermediate, AFB1-8,9-epoxide, 
which in turn reacts with macromolecules 
such as lipid and DNA. This leads to lipid 
peroxidation and cellular injury (Stresser et 
al., 1994). In the present study a significant 
reduction in the levels of hepatic GSH and 
serum protein thiols were observed in the 
AFB1 group. This was demonstrated previ-
ously and the depletion of liver GSH may 
be attributed to its conjugation with the 
electrophilic metabolites (Mitchell et al., 
1973; Liu et al., 1999; Meki et al., 2001; 
Umarani et al., 2008). Similarly to another 
report (Wang et al., 1991), the present study 
found no significant change in hepatic GPx 
and GR activities in the AFB1-received 
group. Siegers et al. (1982) demonstrated 
that the depletion of hepatic GSH below a 
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critical threshold-concentration allowed the 
enhancement of lipid peroxidation evoked 
by exogenous promotors, while the GPx 
remains unaffected. Therefore, this insig-
nificant change in hepatic GPx may be at-
tributed to the reduction of hepatic GSH 
level. 
The significant increase in serum activi-
ties of ALT, AST and ALP that is observed 
in AFB1-treated group (Table 1) is an indi-
cator of the toxic liver damage induced by 
AFB1. This result is in agreement with 
Moundipa and Domngang (1991). Similar 
results have also been reported in other pre-
vious studies (Pelissier et al., 1992; Liu et 
al., 2001; Preetha et al., 2006). 
The apparent decrease in the hepatic lev-
els of DNA and RNA observed in the AFB1 
– treated group is similar to the observation 
of Liu et al. (1988) and Abdel-Wahhab et 
al. (2006). Several processes seem to con-
tribute to this apparent decrease. One possi-
bility is the loss of AFB1-DNA adducts 
from the liver by cell death. Indeed, after in 
vivo or in vitro activation by cytochrome 
P450, AFB1 binds preferentially to physio-
logically active regions of rat liver nuclear 
chromatin (Yu, 1983). There is subsequent 
depression of nucleic acid synthesis (Neal 
and Ghabral, 1980) causing fixation of mo-
lecular lesions, which ultimately leads into 
cancer cells (Essigmann et al., 1982). 
Moreover, the N7 position of guanine ap-
pears to be the only site of hepatic AFB1-
DNA adduct formation in humans as well 
as in experimental animals (Wogan, 1992). 
Attachment at this position of the purine 
base in DNA labializes both the imidazole 
ring and glycosyl bond rendering it unstable 
(Groopman et al., 1981). 
Regarding the effect of vitamin E and se-
lenium supplementation on AFB1-induced 
liver injury, this study showed that vitamin 
E and selenium significantly decreased the 
elevated level of hepatic MDA and in-
creased the reduced level of hepatic GSH 
level. Moreover, our results showed nor-
malization of hepatic GSH level in the vi-
tamin E and Se-treated group, and increase 
in the activities of both hepatic GR and G-
6-PDH. Our results are consistent with that 
of Cassand et al. (1993) and Shen et al. 
(1994) who demonstrated that treatment 
with vitamin E and selenium, both antioxi-
dants, significantly inhibited lipid peroxida-
tion as well as liver cell damage. In addi-
tion, the apparent increase in hepatic GPx 
activity shown in the current study can be 
attributed to the fact that vitamin E and se-
lenium are reinforcing each other in their 
actions. Vitamin E reduces selenium re-
quirement by preventing loss of selenium 
from the body, which is explained by sele-
nium as an integral part of the enzyme glu-
tathione peroxidase (Rotruck et al., 1973). 
Cellular exposure to xenobiotics and anti-
oxidants leads to coordinated induction of a 
battery of genes encoding detoxifying en-
zymes including GST (Venugopal et al., 
1997). The increase in hepatic GST activity 
in the vitamin E and selenium group re-
vealed in this study can therefore be re-
sponsible for the reduction of AFB1 toxicity 
because GST has been shown to play a 
critical role in preventing the binding of 
AFB1 to DNA (Hayes et al., 1991b). 
Moreover, normalization of serum AST, 
ALP, and decrease in ALT activities were 
achieved relative to control and AFB1 
groups, respectively in the vitamin E 
+ selenium-treated group. The decrease in 
the elevated ALT and AST activities may 
be attributed to the decrease in oxidative 
stress through the antioxidant properties of 
vitamin E and selenium whereas the de-
crease in serum ALP may be attributed to a 
reduction in bile duct proliferation by vita-
min E (Zamora et al., 1991; Souza et al., 
1999). On the other hand, treatment with 
vitamin E and selenium did not modulate 
the hepatic levels of DNA and RNA. Vita-
min E, a lipid soluble inhibitor of lipid per-
oxidation, may not be able to prevent the 
binding of AFB1 metabolites to DNA dur-
ing the initiation process of cellular injury, 
which occurs in the hydrophilic intracellu-
lar compartment (Stresser et al., 1994).  
Regarding the effect of β-carotene intake 
on the AFB1-induced hepatic injury, the 
present study revealed normalization of he-
patic GSH and serum of protein thiols lev-
els relative to control group in the β-
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carotene-treated group. In addition, there 
was significant increase in the hepatic GPx 
and GR activities as compared to the AFB1-
treated group that may be explained by the 
antioxidant property of β-carotene. β-
carotene may play a role in trapping peroxy 
free radicals in tissues and by functioning 
as a scavenger of singlet oxygen at low 
oxygen partial pressures (Burton and In-
gold, 1984). A further explanation of the 
carotenoid action is their conversion into 
retinoids. Indeed, since β-carotene has the 
highest provitamin A activity, this hypothe-
sis is attractive and is supported by the 
demonstration that vitamin A and β-
carotene reversed oral leukoplakias in to-
bacco chewers but that canthaxanthin (a 
carotenoid without provitamin A activity), 
was without effect (Stich et al., 1984). In 
consequence, the present study showed that 
β-carotene intake resulted in a decrease of 
ALT and normalization of ALP in serum 
relative to AFB1 and control groups, respec-
tively. 
The current study showed no significant 
change in the elevated level of hepatic 
MDA in the β-carotene-treated group. This 
might be explained by the ability of β-
carotene to inhibit transformation, and their 
ability to up-regulate junctional communi-
cation without inhibiting the formation of 
MDA (taken as an index of lipid peroxida-
tion) (Zhang et al., 1991). The observed in-
crease in hepatic GST and cytochrome c-
reductase activities in the β-carotene-treated 
group is related to the conversion of β-
carotene to vitamin A derivatives, and the 
ability of vitamin A to induce P450 enzy-
matic system including cytochrome c-
reductase (Bhattacharya et al., 1989; Koch 
et al., 1990). 
Normalization in the hepatic level of 
RNA in the β-carotene- treated group could 
be due to the action as a protective agent of 
DNA nucleophilic sites and thus could in-
fluence the AFB1-DNA formation. It has 
also been reported that vitamin A readily 
forms epoxides, such as 5,6-epoxyretinoic 
acid, which can compete with mutagenic 
epoxides in reacting with DNA (De Flora, 
1988). Moreover, retinol binding to chro-
matin may change the accessibility of DNA 
to xenobiotics and intercalation of AFB1 
epoxide on DNA (Harris et al., 1989). 
This study showed that silymarin a stan-
dard hepato-protective, restored the ele-
vated level of hepatic MDA and apparently 
increased hepatic GPx activity. The is due 
to the inhibition of lipid peroxidation 
caused by silymarin free radical-scavenging 
properties (Dehmlow et al., 1996; Rastogi 
et al. 2001; Farghali et al., 2000). This 
hepato-protective antioxidant property of 
silymarin was shown in the present study to 
consequently restore ALT and ALP and to 
decrease AST activities in serum relative to 
the control and AFB1 groups, respectively. 
Silymarin was reported to improve the 
functional markers of liver damage (Lang et 
al., 1990; Preetha et al., 2006) and silymarin 
and silybinin have been demonstrated to act 
as cell membrane stabilizers (Fraschini et 
al., 2002). 
Silymarin also produced significant in-
crease in the hepatic level of RNA as com-
pared to the AFB1-treated group. The in-
crease in the hepatic level of RNA is in 
agreement with reports that silymarin has a 
stimulating influence on proliferation, RNA 
synthesis and protein synthesis in liver cells 
(Sonnenbichler and Zetl, 1987). Silymarin 
increases the rate of RNA synthesis through 
stimulation of nucleolar polymerase 1 (Fra-
schini et al., 2002). Normalization of the 
hepatic RNA level was also observed in the 
silymarin group as compared to the control 
group. 
This study showed that coenzyme Q10 
restored the elevated hepatic MDA level 
and increased the activities of hepatic GPX, 
GR and GST as compared to the control 
and AFB1-treated groups, respectively. This 
decrease in hepatic MDA level and the con-
sequent increase in hepatic GPX and GR 
activities may be attributed to the antioxi-
dant property of coenzyme Q10 (Mellors and 
Tappel, 1966). Both the oxidized and re-
duced form of coenzyme Q10 is found in all 
cellular membranes where they have been 
suggested to protect membrane phospholip-
ids and proteins against oxidative damage 
(Ernster and Dallner, 1995). Leibovitz et al. 
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(1990) suggested that the increase in he-
patic GPx is attributed to the presence of an 
inverse relationship between tissue GPx and 
TBARS released. Consequently, normaliza-
tion in the serum activities of ALT and 
AST along with a significant decrease in 
ALP has been observed in the coenzyme 
Q10-treated group relative to the control and 
AFB1 groups, respectively. This effect may 
be related to the effectiveness of coenzyme 
Q10 in suppressing the increased lipid per-
oxidation and destruction of the hepatocyte 
membrane in the regenerating liver cells of 
rats as reported previously by Okuyama et 
al. (1991). Moreover, coenzyme Q10 exhib-
its protection against liver damage by low-
ering TBARS and alanine release leading to 
decrease in serum enzyme activities 
(Zamora et al., 1991). The liver also repre-
sents the target organ for coenzyme Q10 on 
investigating the distribution of coenzyme 
Q10 into different rat tissues as reported pre-
viously by Scalori et al. (1990).  
It can be concluded that the hepatotoxic-
ity induced by aflatoxin B1 seemed to be 
modulated effectively by the simultaneous 
use of antioxidants: vitamin E and selenium 
combination, β-carotene, silymarin or coen-
zyme Q10. Moreover, vitamin E and sele-
nium combination and β-carotene are more 
efficient than coenzyme Q10 and silymarin 
in modulating the liver antioxidant enzy-
matic system. It is highly recommended to 
eat well-balanced and nutritious diets that 
contain sufficient amounts of natural anti-
oxidants as a way to counteract the delete-
rious effects of the environmental hepato-
toxins, including aflatoxin B1. These dietary 
antioxidants typically boost the liver's 
health and can minimize any excess damage 
done to the liver and may even expedite 
liver recovery. 
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